keyboard_arrow_up

Male Infertility - Pipeline Review, H1 2014

Restoring male infertility condition through different therapeutics

 

Mumbai, India – June 9, 2014 - In infertile relationships, the male factor contributes about 50%. The male infertility research found that men with non-obstructive azoopermia do not have the capability to produce biological children. Even with the surgical micro dissection testicular sperm extraction, the success rate for most patients is low, calling for new therapeutic approaches and drugs that will treat this condition.

 

This report: Male Infertility - Pipeline Review, H1 2014 provides snapshots on global therapeutic scenario for Male Infertility. Featuring synopsis on investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications, this report provides a comprehensive information on the therapeutic development complete with comparative analysis.

 

Stem cell therapy for male infertility

30% of couples face infertility issues due to the male partner alone. The success rate of the available treatment solution is not high, leading to healthcare professionals opting for other approaches like the stem cell therapy. The stem cells are able to differentiate the functional cell types giving rise to regenerative medicine procedures. Investigators are currently developing methods using stem cells to correct or restore male fertility as they focus on its therapeutic potential.

 

Oral medications therapy

Certain oral drugs are capable to treat defined abnormalities in the male reproductive tract. Investigators are formulating anti-inflammation medication, hormone-regulating medications and other anti-bacterial medicines to improve sperm motility, testosterone production, and reduce free oxygen radicals in patients suffering with male infertility.

 

Biosimilar FSH agonist for infertility

Follicle stimulating hormone (FSH) is an important component for male and female fertility. Recently FSH biosimilars obtained marketing authorization by the European Medicines Agency, however, the FSH biosimilar male infertility treatment is still in clinical trials as the costs and results involved is far from being established. Furthermore, the pros and cons of its long-term applications are still not known rendering the treatment in the pipeline and under review.

 

Male infertility occurs due to multiple reasons. Even if surgical procedures exists and may cure the condition, the process is not always 100% guaranteed. This led to researchers investigate alternative male infertility treatment methods that will improve the situation. From various kinds of biosimilars to the use of stem cell therapy, there are a number of therapies in the pipeline.

 

For further insights,

 

Visit: http://www.researchonglobalmarkets.com/male-infertility-pipeline-review-h1-2014.html

 

About Research on Global Markets

 

Research on Global Markets is a leading source for market research on various sectors globally, offering premium research content from worldwide publishers of market research reports. Our database hosts premium market research content developed by global publishers. It offers premium industry research reports, company profiles and country briefs. We have a dedicated team of research professionals who can facilitate, in an unbiased manner, the process of identifying appropriate market research reports that are targeted to fulfill all your information-related requirements.

 

For more details on the content of each report and ordering information please contact:

 

Email: customerservice@researchonglobalmarkets.com

US:  +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

Blog:  blog.researchonglobalmarkets.com